Greek NHS capacity constraints regarding intravenous treatment for rheumatoid arthritis patients.
Intravenous (iv) infusion of biologic agents is a highly effective therapeutic option for active rheumatoid arthritis (RA). In Greece, it is mandatory that all infusions are administered in a hospital setting; therefore, they are strongly correlated with the system's capacity in terms of resources. The objective of this paper was to assess the capacity of the Greek National Health System (NHS) hospitals to meet current/projected demand for iv treatment of RA patients. Semi-qualitative interviews on the basis of a strictly structured questionnaire were conducted with the Heads of all NHS RA infusion sites to record available resources, service utilization and ability to meet current/projected demand. Out of 31 NHS infusion sites, 28 responded (90.3%). On average, 41.6% of Greek NHS RA patients are treated with a biologic agent and 61.5% of respondents stated that available resources are insufficient to meet current demand. The most important constraints in selection order were as follows: space (93%), staff (89.5%), equipment (61.5%) and working hours (57%). Fifty-six percent of respondents stated that they may decline treatment to patients due to constraints. Overall, respondents estimated that the number of iv patients could be increased by 104%, were there no capacity constraints. An important proportion of the estimated 40.000 RA patients in Greece, for whom iv biologic treatment in the hospital setting is essential for disease control, may be declined treatment due to constraints in RA-specific resources. Rationalization and reallocation of NHS resources is required to ensure equity in access to effective treatment for all RA patients.
Department of Health Economics, National School of Public Health, 196 Alexandras Avenue, 11521 Athens, Greece. kathanasakis@esdy.edu.gr
Kostas
K
Athanasakis
Marios
M
Detsis
Kyriakos
K
Souliotis
Christina
C
Golna
John
J
Kyriopoulos
D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics; D006115:Greece; D019538:Health Care Surveys; D006295:Health Resources / Q000191:economics / Q000458:organization & administration*; D006297:Health Services Accessibility / Q000191:economics / Q000458:organization & administration*; D006801:Humans
D018501:Antirheumatic Agents
Rheumatology (Oxford). 2000 Jun;39(6):603-11
10888704
Ann Rheum Dis. 2006 Sep;65(9):1175-83
16540552
Eur J Health Econ. 2008 Jan;8 Suppl 2:95-106
18157559
Rheumatology (Oxford). 2006 Nov;45(11):1376-9
17040892
Health Policy. 2005 Oct;74(2):167-80
16153477
Appl Health Econ Health Policy. 2003;2(3):129-34
14984277
Joint Bone Spine. 2008 Jul;75(4):408-15
18455949
Curr Opin Rheumatol. 2004 May;16(3):177-9
15103241
Rheumatology (Oxford). 2006 Dec;45(12):1549-54
16690763
Rheumatology (Oxford). 2002 Jul;41(7):793-800
12096230
Br J Rheumatol. 1997 May;36(5):551-9
9189057
Am J Phys Med Rehabil. 2005 Sep;84(9):702-11
16141749
Joint Bone Spine. 2004 Nov;71(6):518-24
15589432
N Engl J Med. 2001 Mar 22;344(12):907-16
11259725
Value Health. 2005 Sep-Oct;8(5):581-90
16176496
Arthritis Rheum. 1994 Apr;37(4):481-94
8147925
Am J Manag Care. 2002 Mar;8(3):231-40
11915973
Eur J Health Econ. 2008 Jan;8 Suppl 2:S49-60
18157732
Autoimmun Rev. 2005 Mar;4(3):130-6
15823498
J Rheumatol. 1998 Jan;25(1):44-50
9458201
Arthritis Rheum. 2003 Jan;48(1):54-8
12528103
Best Pract Res Clin Rheumatol. 2003 Oct;17(5):831-46
12915160
Clin Rheumatol. 2010 Jun;29(6):645-57
20127397
Semin Arthritis Rheum. 2006 Dec;36(3):182-8
17045630